Product Catalog



> Recombinant Protein > E.Coli Expressed > Canine EGF / Epidermal Growth Factor (aa 973-1024) Protein (Native) Canine EGF / Epidermal Growth Factor (aa 973-1024) Protein (Native)
| Catalog | Size (Price) | Quantity | In Stock | Operation | Other Information |
| 70013-DNAE |
|
YES |
|
![]() |
|
Epidermal Growth Factor Protein Datasheet
EGF / Epidermal Growth Factor Protein Price Inquiry ( Available Sizes )
- ≥1mg Bulk: Inquiring Price
EGF / Epidermal Growth Factor Protein Product Information
| Synonym : | EGF |
| Protein Construction: |
A DNA sequence encoding the canine EGF (Q9BEA0)(Asn973-Arg1024)was expressed , with a N-terminal Met. |
| Source: | Canine |
| Expression Host: | E.coli |
EGF / Epidermal Growth Factor Protein QC Testing
| Purity: | > 95% as determined by SDS-PAGE | SDS-PAGE:![]() EGF / Epidermal Growth Factor protein |
| Endotoxin: | Please contact us for more information. | |
| Stability: | Samples are stable for up to twelve months from date of receipt at -70℃ | |
| Predicted N terminal: | Met | |
| Molecular Mass: |
The recombinant canine EGF comprises 53 amino acids and has a predicted molecular mass of 6.3 kDa. The apparent molecular mass of the protein is approximately 7 kDa in SDS-PAGE under reducing conditions due to glycosylation. |
|
| Formulation: | Lyophilized from sterile PBS.
|
EGF / Epidermal Growth Factor Protein Usage Guide
| Storage: | Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution: | A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information. |
EGF / Epidermal Growth Factor Protein Related Products & Topics
Related Areas:
Cancer>>Cancer Biomarkers>>EGF
Cancer>>Growth Factor & Receptor>>EGF Family & Receptor>>EGF
Proteins:
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| EGF | Human | EGF/Fc Protein, Recombinant![]() |
10605-H01H |
| EGF | Human | EGF Protein, Recombinant![]() |
10605-HNAE |
| EGF | Mouse | EGF Protein, Recombinant | 50482-M01H |
| EGF | Canine | EGF / Epidermal Growth Factor Protein, Recombinant | 70013-D07E |
| EGF | Canine | EGF / Epidermal Growth Factor (aa 973-1024) Protein, Recombinant, with Native | 70013-DNAE |
Antibodies:
| Molecule | Application | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| Human EGF |
WB, ELISA | EGF Antibody, Rabbit MAb | 10605-R008 |
EGF / Epidermal Growth Factor Protein Description
Epidermal growth factor (EGF), also known as urogastrone (URG) since it was isolated from urine based on its inhibitory effect on gastric secretion, is the founding member of the EGF-family of growth factors. All the members of this protein family have highly similar structural and functional characteristics. EGF is initially synthesized as a 130 kDa single-pass transmembrane protein containing 9 EGF-like units and 9 LDL-receptor class B repeats. The mature soluble EGF is a 6 kDa peptide corresponding to the EGF unit located proximal to the transmembrane domain. EGF is expressed in kidney, salivary gland, cerebrum and prostate, and plays an important role in the regulation of cell growth, proliferation, and differentiation by binding to its receptor EGFR. As a potent mitogen, EGF stimulates the growth of various epidermal and epithelial tissues both in vivo and in vitro. Furthermore, EGF is also identified as a magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Defects in EGF are the cause of hypomagnesemia type 4 (HOMG4), a disorder characterized by massive renal hypomagnesemia and normal levels of serum calcium and calcium excretion.
References
- Ciardiello F. et al., 1991, Proc Natl Acad Sci. 88: 7792-6.
- Gout I. et al., 1992, Biochem J. 288: 395-405.
- Harris RC. et al., 2003, Exp Cell Res. 284: 2-13.
- Dreux AC. et al., 2006, Atherosclerosis. 186: 38-53.
- Groenestege WMT. et al., 2007, J Clin Invest. 117: 2260-7.

+86-400-890-9989








